Rankings
▼
Calendar
SUPN Q2 2016 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q2 2016 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$50M
Gross Profit
$48M
94.5% margin
Operating Income
$10M
20.7% margin
Net Income
$10M
20.3% margin
EPS (Diluted)
$0.18
QoQ Revenue Growth
+17.1%
Cash Flow
Operating Cash Flow
$17M
Free Cash Flow
$16M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$219M
Total Liabilities
$78M
Stockholders' Equity
$141M
Cash & Equivalents
$60M
← FY 2016
All Quarters
Q3 2016 →
